Cello Therapeutics, Inc.

Cello Therapeutics, Inc. is a biotechnology startup founded in April 2016 that focuses on developing innovative nanoparticles for cancer treatment. The company's nanoparticles, consisting of FDA-approved cancer drugs loaded within a biocompatible polymer core and coated with natural red blood cell membrane, represent a groundbreaking technology in the field of nanomedicine. This unique approach allows the nanoparticles to evade immune responses, enabling extended circulation in the bloodstream for enhanced drug delivery to tumor sites, thereby offering distinct performance advantages for oncological applications. Currently, the company is in the drug development and testing stage. Cello Therapeutics, Inc. licenses technology and laboratory protocols for nanoparticle development from its parent company, Arytha Biosciences, LLC. Additionally, the company benefits from its sibling entity, Cellics Therapeutics, Inc., which specializes in nanoparticle development for biodetoxification and the treatment of infectious diseases, providing engineering expertise in membrane-coating technology. The company's most recent funding round, a $7.05 million Venture Round investment, took place on August 22, 2022. Although the information about the specific investors is not available, this investment showcases confidence in the potential of Cello Therapeutics, Inc.'s innovative approach to cancer treatment. Located in the United States, the company holds promise in advancing the field of cancer therapy through its pioneering nanoparticle technology.